Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunolo
Go back to Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunolo| (NASDAQ: NRIX) | Delayed: 26.14 +0.82 (3.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.32 | 52 Week High | $ | |||
| Open | $25.19 | 52 Week Low | $ | |||
| Day High | $26.22 | P/E | N/A | |||
| Day Low | $24.97 | EPS | $ | |||
| Volume | 1,232,152 | |||||
